Aim and Objectives: The study aimed to study the clinical evaluation of Parkinson’s disease in detail and to assess the efficacy of selected Unani formulations in the management of Parkinson’s disease. Material and Methods: The study was designed as a randomized single-blind comparative study with a sample size of 20. Ten patients in each groups A and B were randomly selected. The formula A contains Waj, Aqarqarha, Tukhm e Konch, Asgand, Kulanjan and the formula B contains Shehad and Usthukhudoos. The subjective parameters like tremors, slow movements, impaired posture, rigid muscles, and facial expressions were reduced significantly in both groups. Parkinson's disease questionnaire – 39 (PDQ - 39) was used as an objective parameter. Results: The overall response in group A revealed that 09 (90%) of patients had a satisfactory response to their clinical symptoms and signs and 01 (10%) patient was found in the categories of poor response whereas in group B 07 (70%) of patients had a satisfactory response from their clinical symptoms and signs and 03 (30%) patients were found in the categories of poor response. Moreover, both groups were found safe without any adverse effects. Conclusion: It can be concluded that the drugs of groups A and B produced a significant effect in the treatment of Parkinson's disease. However, the biological mechanisms through which the group A and B drugs reduce the clinical symptoms and signs remain unclear and need to be validated with experimental and clinical studies.